Collaboration Revenues was Lineage Cell Therapeutics’s largest product and service line in fiscal 2025, bringing in $13.61M of $14.56M (93%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenues | $13.37M | $7.59M | $8.15M | $13.61M | |||||
| Grant | — | — | — | — | |||||
| Grant Revenue | — | — | — | — | |||||
| Royalties | — | — | — | — | |||||
| Royalties, License & Other Revenues | $1.34M | $1.36M | $1.35M | $947.00K | |||||
| Royalties From Product Sales & License Fees | — | — | — | — | |||||
| Grant Revenues | — | — | — | — | |||||
| Subscription & Advertisement Revenues | — | — | — | — | |||||
| Sale Of Research Products & Services | — | — | — | — | |||||
| Total | $14.70M | $8.95M | $9.50M | $14.56M |
Lineage Cell Therapeutics brought in $14.56M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 53.2% from $9.50M in fiscal 2024. Collaboration Revenues was the largest at $13.61M (93.5%), ahead of Royalties, License & Other Revenues at $947.00K (6.5%).
Compared with fiscal 2024, Collaboration Revenues grew 67.0% to $13.61M, while Royalties, License & Other Revenues fell 29.9% to $947.00K. From fiscal 2022 to 2025, combined revenue from these lines fell from $14.70M to $14.56M, a compound annual decline of 0.3%. Collaboration Revenues' share of the total rose from 90.9% to 93.5%.
United States was Lineage Cell Therapeutics’s largest region in fiscal 2021, bringing in $3.90M of $4.34M (90%).
| Geography | FY 2012 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|
| Revenue From Area Of Domestic | — | — | — | — | |
| United States | $1.80M | $2.09M | $1.16M | $3.90M | |
| Foreign | $3.18M | $1.42M | $666.00K | $446.00K | |
| Asia | — | — | — | — | |
| Total | $4.99M | $3.52M | $1.83M | $4.34M |
Lineage Cell Therapeutics brought in $4.34M from its two regions in fiscal 2021, the year ended December 31, 2021. That was up 137.7% from $1.83M in fiscal 2020. United States was the largest at $3.90M (89.7%), ahead of Foreign at $446.00K (10.3%).
Compared with fiscal 2020, United States grew 235.8% to $3.90M, while Foreign fell 33.0% to $446.00K. From fiscal 2018 to 2021, combined revenue from these regions fell from $4.99M to $4.34M, a compound annual decline of 4.5%. United States' share of the total rose from 36.2% to 89.7%.
Lineage Cell Therapeutics (LCTX) reports its revenue by product and service and by geography. In fiscal 2025, Collaboration Revenues was its largest product and service line, bringing in $13.61M (93.5% of the total), followed by Royalties, License & Other Revenues at $947.00K (6.5%).
Collaboration Revenues was Lineage Cell Therapeutics' largest product and service line in fiscal 2025, bringing in $13.61M, or 93.5% of the $14.56M total across its two product and service lines.
United States was Lineage Cell Therapeutics' largest region in fiscal 2021, bringing in $3.90M, or 89.7% of the $4.34M total across its two regions.
Collaboration Revenues grew faster than Royalties, License & Other Revenues in fiscal 2025, up 67.0% from $8.15M to $13.61M. Royalties, License & Other Revenues fell 29.9% to $947.00K.
Every figure comes from Lineage Cell Therapeutics' annual financial filings, as reported. Each line keeps the name Lineage Cell Therapeutics gives it, and years follow its fiscal calendar.
Lineage Cell Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.